Prevention and treatment of venous thromboembolism in cancer patients

Lyman GH et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33:654–656. https://doi.org/10.1200/JCO.2014.59.7351

Farge D et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17:e452–e466. https://doi.org/10.1016/S1470-2045(16)30369-2

Meyer G et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729–1735. https://doi.org/10.1001/archinte.162.15.1729

Lee AY et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153. https://doi.org/10.1056/NEJMoa025313

Deitcher SR et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389–396. https://doi.org/10.1177/1076029606293692

Hull RD et al (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072. https://doi.org/10.1016/j.amjmed.2006.02.022

Lee AYY et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314:677–686. https://doi.org/10.1001/jama.2015.9243

Raskob GE et al (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3:e379–e387. https://doi.org/10.1016/S2352-3026(16)30057-6

Young AM et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36:2017–2023. https://doi.org/10.1200/JCO.2018.78.8034

Agnelli G et al (2020) Apixaban for the treatment of venous Thromboembolism associated with cancer. N Engl J Med 382:1599–1607. https://doi.org/10.1056/NEJMoa1915103

Khorana AA et al (2019) Rivaroxaban for Thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380:720–728. https://doi.org/10.1056/NEJMoa1814630

Carrier M et al (2019) Apixaban to prevent venous Thromboembolism in patients with cancer. N Engl J Med 380:711–719. https://doi.org/10.1056/NEJMoa1814468

Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107:I-17–I-21. https://doi.org/10.1161/01.CIR.0000078466.72504.AC

Otten HM, Prins MH, Smorenburg SM, Hutten BA (2000) Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 30(Suppl 2):72–76. https://doi.org/10.1159/000054167 (discussion 63)

Clagett GP, Reisch JS (1988) Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 208:227–240. https://doi.org/10.1097/00000658-198808000-00016

Shen VS, Pollak EW (1980) Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 73:841–843. https://doi.org/10.1097/00007611-198007000-00005

Prandoni P et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488. https://doi.org/10.1182/blood-2002-01-0108

Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J (1997) Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost 78:121–125

Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P (1998) Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 83:180–185. https://doi.org/10.1002/(sici)1097-0142(19980701)83:1〈180::aid-cncr24〉3.0.co;2‑s

Gardlund B (1996) Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 347:1357–1361. https://doi.org/10.1016/s0140-6736(96)91009-0

Key NS et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: aSCO clinical practice guideline update. J Clin Oncol 38:496–520. https://doi.org/10.1200/JCO.19.01461

Konstantinides SV et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543–603. https://doi.org/10.1093/eurheartj/ehz405

Kahale LA et al (2018) Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006650.pub5

Sobieraj DM et al (2018) Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost. https://doi.org/10.1177/1076029618800792

Douketis JD, Crowther MA, Foster GA, Ginsberg JS (2001) Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 110:515–519. https://doi.org/10.1016/s0002-9343(01)00661-1

Khorana AA et al (2017) Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost 1:14–22. https://doi.org/10.1002/rth2.12002

Mazzolai L et al (2018) Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 39:4208–4218. https://doi.org/10.1093/eurheartj/ehx003

Schulman S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352. https://doi.org/10.1056/NEJMoa0906598

Schulman S et al (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772. https://doi.org/10.1161/CIRCULATIONAHA.113.004450

Investigators E‑P et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. https://doi.org/10.1056/NEJMoa1113572

Investigators E et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510. https://doi.org/10.1056/NEJMoa1007903

Agnelli G et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808. https://doi.org/10.1056/NEJMoa1302507

Sprynger M (2013) Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Rev Med Liege 68:548–551

Schulman S et al (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114:150–157. https://doi.org/10.1160/TH14-11-0977

Prins MH et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1:e37–e46. https://doi.org/10.1016/S2352-3026(14)70018-3

Carrier M et al (2014) Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134:1214–1219. https://doi.org/10.1016/j.thromres.2014.09.039

van der Hulle T et al (2014) Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 12:1116–1120. https://doi.org/10.1111/jth.12605

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S., Standardization Committee of the International Society on T. & Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

Kraaijpoel N et al (2018) Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 118:1439–1449. https://doi.org/10.1055/s-0038-1667001

Kirkilesis GI, Kakkos SK, Tsolakis IA (2019) Editor’s choice—A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg 57:685–701. https://doi.org/10.1016/j.ejvs.2018.11.004

Launay-Vacher V et al (2007) Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376–1384. https://doi.org/10.1002/cncr.22904

Levy JH, Spyropoulos AC, Samama CM, Douketis J (2014) Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv 7:1333–1351. https://doi.org/10.1016/j.jcin.2014.06.014

Kearon C et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352. https://doi.org/10.1016/j.chest.2015.11.026

Samuelson Bannow BT et al (2018) Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 16:1246–1249. https://doi.org/10.1111/jth.14015

Levy JH, Douketis J, Weitz JI (2018) Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 15:273–281. https://doi.org/10.1038/nrcardio.2017.223

Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R (2018) Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. Crit Rev Oncol Hematol 132:169–179. https://doi.org/10.1016/j.critrevonc.2018.09.015

Short NJ, Connors JM (2014) New oral anticoagulants and the cancer patient. Oncologist 19:82–93. https://doi.org/10.1634/theoncologist.2013-0239

Steffel J et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393. https://doi.org/10.1093/eurheartj/ehy136

Parasrampuria DA et al (2016) Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol 82:1591–1600. https://doi.org/10.1111/bcp.13092

Aisenberg J et al (2018) Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation-Thrombolysis in myocardial infarction). Circ Cardiovasc Qual Outcomes 11:e3998. https://doi.org/10.1161/CIRCOUTCOMES.117.003998

Flack KF et al (2017) Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran to prevent stroke and systemic embolism from atrial fibrillation. Clin Gastroenterol Hepatol 15:682–690. https://doi.org/10.1016/j.cgh.2016.10.011

Francis CW et al (2015) Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 13:1028–1035. https://doi.org/10.1111/jth.12923

Jara-Palomares L et al (2017) Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res 157:90–96. https://doi.org/10.1016/j.thromres.2017.07.004

Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M (2018) Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16:1288–1295. https://doi.org/10.1111/jth.14156